AUD210.27
1.23% today
Australia, Sep 01, 08:10 am CET
ISIN
AU000000CSL8
Symbol
CSL

CSL Stock price

AUD210.27
-53.78 20.37% 1M
-49.64 19.10% 6M
-69.06 24.72% YTD
-90.86 30.17% 1Y
-71.88 25.48% 3Y
-54.64 20.62% 5Y
+131.45 166.78% 10Y
+201.71 2,357.32% 20Y
Australia, Closing price Mon, Sep 01 2025
-2.62 1.23%
ISIN
AU000000CSL8
Symbol
CSL
Industry

Key metrics

Basic
Market capitalization
AUD103.0b
Enterprise Value
AUD117.3b
Net debt
AUD14.3b
Cash
AUD3.3b
Shares outstanding
484.2m
Valuation (TTM | estimate)
P/E
22.6 | 19.4
P/S
4.3 | 4.1
EV/Sales
4.9 | 4.7
EV/FCF
29.9
P/B
3.5
Dividends
DPS
AUD4.55
Yield 1Y | 5Y
2.1% | 1.3%
Growth 1Y | 5Y
14.6% | 9.1%
Payout 1Y | 3Y
48.2% | 49.2%
Increased
4 Years
Financials (TTM | estimate)
Revenue
AUD23.8b | AUD25.1b
EBITDA
AUD7.8b | AUD8.9b
EBIT
AUD6.3b | AUD7.7b
Net Income
AUD4.6b | AUD5.3b
Free Cash Flow
AUD3.9b
Growth (TTM | estimate)
Revenue
5.1% | 5.4%
EBITDA
7.8% | 27.7%
EBIT
7.7% | 22.7%
Net Income
13.6% | 15.8%
Free Cash Flow
70.2%
Margin (TTM | estimate)
Gross
51.9%
EBITDA
32.9% | 35.6%
EBIT
26.4%
Net
19.3% | 21.2%
Free Cash Flow
16.5%
Financial Health
Equity Ratio
49.1%
Return on Equity
15.5%
ROCE
11.9%
ROIC
10.4%
Debt/Equity
0.6
More
EPS
AUD9.4
FCF per Share
AUD8.1
Short interest
-
Employees
33k
Rev per Employee
AUD730.0k
Show more

Is CSL a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

CSL Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a CSL forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a CSL forecast:

Buy
86%
Hold
14%

Financial data from CSL

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
23,793 23,793
5% 5%
100%
- Direct Costs 11,438 11,438
5% 5%
48%
12,355 12,355
5% 5%
52%
- Selling and Administrative Expenses 4,001 4,001
8% 8%
17%
- Research and Development Expense 2,078 2,078
5% 5%
9%
7,832 7,832
8% 8%
33%
- Depreciation and Amortization 1,555 1,555
8% 8%
7%
EBIT (Operating Income) EBIT 6,276 6,276
8% 8%
26%
Net Profit 4,591 4,591
14% 14%
19%

In millions AUD.

Don't miss a Thing! We will send you all news about CSL directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Paul McKenzie
Employees 32,698
Founded 1961
Website www.csl.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today